Screening of investigational therapeutics to treat, modify or prevent epilepsy for the ninds epilepsy therapy screening program (etsp)

Active Definitive Contract Awarded Last action

Contract number
75N95022C00007
Awardee
Awarding agency
Obligated
$26,486,841

Award facts

Contract value 80% obligated
  • $26,486,841.00 Current, with exercised options
  • $32,975,629.00 Potential, with all options
Completion date 79% complete
  • Current, with exercised options
  • Potential, with all options
Funding agency
National Institute of Neurological Disorders and Stroke National Institutes of Health, Department of Health and Human Services
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Negotiated Proposal / Quote
Pricing
Cost No Fee
Place of performance
Salt Lake City, UT 84112, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00007 $0
Other Administrative Action P00006 $0
Exercise an Option P00005 $5,630,106
Exercise an Option P00004 $5,402,180
Exercise an Option P00003 $5,748,077
Exercise an Option P00002 $5,502,413
Modification $4,204,065
Other Administrative Action P00001 $0

About this award

The National Institute of Neurological Disorders and Stroke awarded a $32.975 million definitive contract to University of Utah for screening of investigational therapeutics to treat, modify, or prevent epilepsy under the NINDS Epilepsy Therapy Screening Program on March 22, 2022, under cost-no-fee pricing with no set-aside.

The originating solicitation calls for screening of investigational compounds using established acute and chronic animal seizure models to support development of epilepsy therapies, including studies on drug-resistant epilepsy and disease prevention and modification. Place of performance is Salt Lake City, UT. The contract period runs through December 31, 2027, comprising a nine-month base period, four one-year option periods, and a three-month transition period.

Service Contract Inventory data shows the contract has generated actual invoiced labor of $4 million in FY2022, $5 million in FY2023, $5.8 million in FY2024, and $3.7 million in FY2025, corresponding to 17.0, 20.8, 24.2, and 26.7 FTEs respectively. Government-paid hourly rates have remained stable at approximately $114–$117 per hour across FY2022–FY2024. The prime self-performed all reported hours with no subcontractors in FY2025.

University of Washington Office of Sponsored Programs was subcontracted on June 3, 2022 to support the screening program; a second subcontract was awarded May 24, 2022. NAICS 541715; PSC R425.

Subawards

Subcontractor Amount Awarded
University Of Washington Screening of investigational therapeutics to treat, modify or prevent epilepsy for the ninds epilepsy therapy screening program (etsp) screening of… $2,473,893
Subcontractor not on record Screening of investigational therapeutics to treat, modify or prevent epilepsy for the ninds epilepsy therapy screening program (etsp) screening of… $584,295

Quick answers

Who was awarded contract 75N95022C00007?

75N95022C00007 was awarded to University Of Utah by National Institute on Drug Abuse (National Institutes of Health) on March 22, 2022.

How much is contract 75N95022C00007 worth?

The government has obligated $26,486,841 on 75N95022C00007. Its potential value, with all options, is $32,975,629.

Which agency awarded contract 75N95022C00007?

National Institute on Drug Abuse (National Institutes of Health) awarded 75N95022C00007, with funding from National Institute of Neurological Disorders and Stroke (National Institutes of Health).

Was contract 75N95022C00007 competed?

The extent of competition for 75N95022C00007 was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award